KRAS and non-small cell lung carcinoma: In this study, KRAS mutation rate was 7.6% (120/1586), and in single organ metastasis, KRAS mutant NSCLC tended to transfer to brain (23.3% vs.11.6%, P = 0.001) and lung (21.7% vs.12.4%, P = 0.012) compared with wild type.